Mathematical modeling of routine biological parameters kinetics in order to predict durable benefit for first-line immunotherapy in metastatic or unresectable melanoma

被引：0
|
作者：
Forestier, Jessica
Daumas, Alice Julie
Richard, Marie-Aleth
Gaudy-Marqueste, Caroline
Benzekry, Sebastien
Malissen, Nausicaa
机构：
[1] Aix Marseille Univ, CHU Timone, APHM, Dermatol & Skin Canc Dept,CRCM Inserm U1068,CNRS, Marseille, France
[2] Aix Marseille Univ, COMPutat Pharmacol & Clin Oncol, Ctr Inria Univ Cote Azur,Inst Paoli Calmettes, Ctr Rech Cancerol Marseille,Inserm U1068,CNRS U72, Marseille, France
[3] Aix Marseille Univ, Assistance Publ Hop Marseille, Dermatol & Skin Canc Dept, CEPCM, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21549
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
    Christiane G. Mutz-Rabl
    Peter Koelblinger
    Lukas Koch
    memo - Magazine of European Medical Oncology, 2023, 16 : 108 - 112
  • [2] Immunotherapy for metastatic melanoma-from little benefit to first-line treatment
    Mutz-Rabl, Christiane G.
    Koelblinger, Peter
    Koch, Lukas
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 (02) : 108 - 112
  • [3] A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma
    Drysdale, Erik
    Peng, Yingwei
    Nguyen, Paul
    Baetz, Tara
    Hanna, Timothy P.
    MELANOMA RESEARCH, 2019, 29 (06) : 635 - 642
  • [4] First-line Therapy of locally advanced, unresectable or metastatic Esophageal Cancer Immunotherapy with Pembrolizumab improves Survival
    Rudesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (09)
  • [5] CROSS-REACTIVITY BETWEEN THE FIRST-LINE CHEMOTHERAPY AND SUBSEQUENT IMMUNOTHERAPY IN PATIENTS WITH UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA
    Hamaya, Tomoko
    Hatakeyama, Shingo
    Ozaki, Kai
    Okita, Kazutaka
    Hashimoto, Yasuhiro
    Ohyama, Chikara
    JOURNAL OF UROLOGY, 2022, 207 (05): : E1017 - E1017
  • [6] Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma
    Schmitt, Andreas M.
    Dumas, Lucy
    Larkin, James
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (01) : 17 - 25
  • [7] Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma
    Xia, Cathy Yi
    Wang, Daniel Ying
    Mason, Robert
    Smith, Jessica Louise
    McKean, Meredith Ann
    Lo, Serigne
    Guminski, Alexander David
    Long, Georgina V.
    Carlino, Matteo S.
    Atkinson, Victoria
    Millward, Michael
    McQuade, Jennifer Leigh
    Amaria, Rodabe Navroze
    Johnson, Douglas Buckner
    Menzies, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Single centre retrospective study of outcomes in patients with metastatic melanoma who progress on first-line immunotherapy
    Yang, Zane
    Arneil, Melissa
    Atkinson, Victoria
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 131 - 132
  • [9] Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study
    Mattila, Kalle E.
    Tiainen, Leena
    Vikkula, Johanna
    Kreutzman, Anna
    Engstrom-Risku, Mia
    Kysenius, Kai
    Hoelsa, Olivia
    Hernesniemi, Sari
    Hemmila, Paeivikki
    Pystynen, Anssi
    Maekela, Siru
    FUTURE ONCOLOGY, 2024,
  • [10] The end of the beginning: PD-1 inhibition as the new standard of care first-line immunotherapy in metastatic melanoma
    Cherington, Chad C.
    Bryce, Alan H.
    MELANOMA MANAGEMENT, 2015, 2 (04) : 305 - 309
12345